Assistant Professor of Medicine, Brigham and Women's Hospital
Cardiology
Dr. Stephen D. Wiviott, MD
|
|
Give Review
Stephen Wiviott practices Cardiology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received awards:"Fellow (FACC)". Stephen Wiviott is a published physician. He published 97 publications, including: 'Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain.
- Causes of late mortality with dual antiplatelet therapy after Coronary stents.
- PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
- Sensitive troponin assays in patients with suspected Acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomog...
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.
- Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction.
- Clinical evidence for oral antiplatelet therapy in Acute coronary syndromes.
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events.
- Risk profile of clinical trial participants--reply.
- New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial.
- Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial.
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents.
- High-Risk Coronary Plaque at Coronary CT Angiography Is Associated with Nonalcoholic Fatty Liver Disease, Independent of Coronary Plaque and Stenosis Burden: Results f...
- Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit.
- Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results From the National Cardiovascular Data Registry (NCDR).
- Effect of darapladib on major coronary events after an Acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
- Clinical trial participation after Myocardial infarction in a national cardiovascular data registry.
- Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: A TRITON-TIMI 38 Su...
- Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in ...
- Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Corona...
- Clinical Implications and Correlates of Q Waves in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY-TIMI 28 Tr...
- Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Sy...
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation.
- Concomitant Administration of Clopidogrel With Statins or Calcium Channel Blockers: Insights From the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcom...
- Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction.
- Discharge Aspirin Dose and Clinical Outcomes in Patients with Acute Coronary Syndromes treated with Prasugrel vs. Clopidogrel: An Analysis from the TRITON-TIMI 38 Study.
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus.
- Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial.
- Prasugrel versus clopidogrel for patients with unstable Angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified...
- Sex differences in the effectiveness of early coronary computed tomographic angiography compared with standard emergency department evaluation for Acute chest pain: th...
- Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51).
- ED administration of thienopyridines in non-ST-segment elevation Myocardial infarction: results from the NCDR.
- Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry.
- Hospital length of stay in patients with non-ST-segment elevation Myocardial infarction.
- Risk of Heart Failure Complication During Hospitalization for Acute Myocardial Infarction in a Contemporary Population: Insights From the National Cardiovascular Data ...
- Coronary CT angiography versus standard evaluation in Acute chest pain.
- Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program.
- Design of the Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography: a multicenter randomized comparative effectiveness trial of cardiac computed ...
- ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial.
- Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry.
- On-clopidogrel platelet reactivity a target in sight?
- Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction.
- Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
- Characteristics and In-Hospital Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary In...
- ILLUMINATE Sheds More Light.
- Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies.
- Use of Emergency Medical Service Transport Among Patients With ST-Segment-Elevation Myocardial Infarction: Findings From the National Cardiovascular Data Registry Acut...
- Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizi...
- Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium.
- Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an Acute coronary syndrome: Observations from the Pravastatin Or ...
- Effect of Prior Stroke on the Use of Evidence-Based Therapies and In-Hospital Outcomes in Patients With Myocardial Infarction (from the NCDR ACTION GWTG Registry).
- No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and Acute myocardial infarction.
- Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation Myocardial infarction, from the National Cardiovascular ...
- When stable becomes unstable: the perils of impersonal medicine.
- Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 ve...
- Comparison of outcomes in patients aged <75, 75 to 84, and ⥠85 years with ST-elevation Myocardial infarction (from the ACTION Registry-GWTG).
- Another step on the road to tailored antiplatelet therapy.
- Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
- Prasugrel.
- Mortality in the TRITON trial: update from the FDA prasugrel action package.
- Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coron...
- Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation Myocardial infarction.
- Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after Acute coronary syn...
- The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with Acute coronary syndromes undergoing percutaneous intervention:...
- Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
- Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
- Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural Myocardial infarction in the Trial to Assess Improvement in Therap...
- Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
- Seasonal variation in lipids in patients following Acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorv...
- Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and Heart failure in patients with ST-elevation myocardial infarction in the TIMI ...
- Cytochrome p-450 polymorphisms and response to clopidogrel.
- Utilization and impact of pre-hospital electrocardiograms for patients with Acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascul...
- Intensity of antiplatelet therapy in patients with Acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
- Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeuti...
- Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with Acute coronary syndromes from the TRITON-TIMI 38 trial.
- Outcomes of patients with Acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [...
- Early and late benefits of prasugrel in patients with Acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improve...
- Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with Acute coronary syndromes.
- Serial measurement of monocyte chemoattractant protein-1 after Acute coronary syndromes: results from the A to Z trial.
- Antiplatelet agents make a comeback in ST-elevation Myocardial infarction.
- Effect of intensive lipid-lowering therapy on mortality after Acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastat...
- New antiplatelet therapies for Acute coronary syndromes.
- Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous Coronary intervention in patien...
- A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
- Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
- Clopidogrel response variability, resistance, or both?
- Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial.
- Clinical relevance of C-reactive protein during follow-up of patients with Acute coronary syndromes in the Aggrastat-to-Zocor Trial.
- The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation Myocardial infarction: the ECG CLARITY-TIMI 28 Study.
- A tale of two trials: a comparison of the post-Acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
- Therapeutic goals for effective platelet inhibition: a consensus document.
- Performance of the thrombolysis in Myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality ...
- Unstable Angina and non-ST-segment elevation myocardial infarction: part II. Coronary revascularization, hospital discharge, and post-hospital care.
- Unstable Angina and non-ST-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care.
- Clopidogrel resistance: a new chapter in a fast-moving story.
- Differential expression of cardiac biomarkers by gender in patients with unstable Angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with A...
Schools
Harvard Medical School
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Dissection
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FACC)
Education
-
Johns Hopkins University -
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1932126471 | |
| NPPES Provider LastName | WIVIOTT | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 230.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1932126471 |
| Last Name Of The Provider | WIVIOTT |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Christopher J. O Donnell, MD |
|
|
Dr. Rajesh Gupta, MD |
|
|
Dr. Marcella A. Calfon, MD |
|
|
Dr. Srinath Adusumalli, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael R. Coronado, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nandita S. Scott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric Ackah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott Kinlay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jae B. Kim, MD |
|
|
Dr. Michael R. Jaff, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan M. Everett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tomas G. Neilan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Milan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lauren E. Frost, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haseeb Jafri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Khalid S. Aljabri, MD |